GlassScriptPhysician profile
Murthy Gollamudi
NPI 1114985439
$2,305.72
in general payments reported to CMS, 2019-2025
24 companies · $704 in 2025
The $704 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $129 · 2021: $269 · 2022: $110 · 2023: $322 · 2024: $292 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,317.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $606.31 | 2019-2022 | |
| Glaxosmithkline, LLC. | $328.30 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $238.58 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $133.61 | 2024-2025 | |
| Insmed, INC. | $133.41 | 2021-2025 | Arikayce, Brinsupri |
| Intuitive Surgical, INC. | $121.47 | 2023 | Da Vinci Surgical System |
| United Therapeutics Corporation | $82.96 | 2021-2023 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $70.12 | 2020-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.32 | 2019-2024 | Stiolto Respimat, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $62.04 | 2022-2024 | Glassia |
| Axsome Therapeutics, INC. | $61.00 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $45.81 | 2023-2024 | Lumryz |
| Baxter Healthcare | $44.50 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $44.44 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $43.01 | 2024 | Xolair |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $39.20 | 2025 | |
| Inspire Medical Systems, INC. | $35.56 | 2023 | Inspire |
| Lilly USA, LLC | $30.04 | 2025 | Zepbound |
| Lundbeck LLC | $28.32 | 2019-2020 | |
| Ambu INC. | $27.27 | 2022 | |
| Inogen, INC. | $19.00 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $16.45 | 2022 | |
| Viatris Specialty LLC | $14.21 | 2025 | Yupelri |
| Abbvie INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murthy Gollamudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.